Top Markets
#1 SODAX SODAX +57.95%
#2 龙虾 (Lobster) 龙虾 (Lobster) +37.44%
#3 Cortex Cortex +32.75%
#4 DexNet DexNet +23.20%
#5 Akedo Akedo +20.15%
#6 wojak wojak +18.68%
#7 Pons Pons +18.10%
#8 MANTRA MANTRA +14.25%
#9 Quack AI Quack AI +14.09%
#10 APEX APEX +13.93%
Coin of the day
SODAX SODAX
Beállítások
Nyelv
MAGYAR
Pénznem
USD
Téma
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
Helyezés a részvények között #7189
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Részvényárfolyam
$38.45
Piaci kapitalizáció
$1.68B
Változás (1 nap)
-1.24%
Változás (1 év)
50.36%
Ország
KR
Kereskedés D&D Pharmatech (347850)

Kategória

Healthcare
D&D Pharmatech (347850) nyeresége
Nyereség ekkor: 2026 TTM: 0
D&D Pharmatech legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége 0. 2026 évben a vállalat 0 nyereséget ért el, megegyezik a 2026 év nyereségéhez, amely 0 volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
D&D Pharmatech nyereségtörténete 2026 és 2026 között
Nyereség az év végén
Év Nyereség Változtassa meg
Nincs elég adat a megadott dátumokhoz.
Hasonló cégek vagy versenytársak nyeresége
Vállalat Nyereség Nyereségkülönbség Ország
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH